Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Michael Mauro EHA 2019


    The Future of CML Therapy: Unmet Medical Needs and New Treatments in Development
    Professor Michael Mauro, Memorial Sloan Kettering Cancer Center New York, USA 

    • Unmet needs in CML: TKI and SCT
    • TKI's in development for CML
    • Development of Asciminib for CML
    • ABL 001X2101: A multicenter, phase 1, first-in-human study
      •  Allosteric inhibition of BCR-ABL
      •  ABL 001X2201: T315l cohort
      • Asciminib phase 3 study Design NCT 03106779
      • Asciminib Phase 2 study design:
        Add-on to first-line imatinib for DMR NCT 03578367
    • PF-114: 3rd generation BCR-ABL

    This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre